Publications by authors named "V Sorodoc"
Article Synopsis
- Obesity is a significant risk factor for venous thromboembolism (VTE) and poses unique challenges in anticoagulation management due to limited research on how extreme body weight affects medication outcomes.
- This review focuses on patients with a body mass index (BMI) of 40 kg/m² or higher, analyzing various anticoagulants' dosages, efficacy, and safety for both prevention and treatment of VTE.
- The study emphasizes the need for personalized treatment strategies and careful monitoring, especially for specific groups like cancer patients or those with kidney issues, given the insufficient evidence available for effective anticoagulant therapy in morbidly obese individuals.
Article Synopsis
- Amiodarone is a highly effective antiarrhythmic drug used to treat conditions like atrial fibrillation and ventricular arrhythmias, functioning across all four classes of antiarrhythmics.
- It has a long half-life and complex pharmacokinetics, which can lead to prolonged effects even after stopping the medication, making regular monitoring for side effects like thyroid issues and lung damage essential.
- This paper aims to offer a detailed review of amiodarone's uses, dosing guidelines, interactions with other medications, and necessary monitoring practices.
Heyde's syndrome (HS) represents an association between aortic stenosis and intestinal angiodysplasias, and it has been demonstrated that acquired von Willebrand disease plays a pivotal role in the pathophysiology of this syndrome. In patients with HS, von Willebrand factor deficiency represents an additional risk factor, further contributing to the risk of bleeding and anemia. We present the case of an 86-year-old patient diagnosed with HS and von Willebrand deficiency in 2018.
View Article and Find Full Text PDFAcute myocardial infarction (AMI) usually represents the clinical manifestation of atherothrombotic coronary artery disease (CAD) resulting from atherosclerotic plaque rupture. However, there are cases in which coronary angiography or coronary computed tomography angiography reveals patients with acute coronary syndrome with non-obstructive CAD. This clinical entity is defined as myocardial infarction with non-obstructive coronary arteries (MINOCA) and often considered as a clinical dynamic working diagnosis that needs further investigations for the establishment of a final etiologic diagnosis.
View Article and Find Full Text PDF(1) Objective: The main aims of our study were to explore the drug survival and effectiveness of secukinumab in patients with axial spondyloarthritis (axSpA). (2) Methods: We underwent a retrospective analysis of consecutive axSpA treated with secukinumab as a first line of biologics or at switch in a biologic-experienced population. Efficacy data, indicating improvement in inflammation parameters (such as C-reactive protein and erythrocyte sedimentation rate) and disease activity scores (such as Ankylosing Spondylitis Disease Activity Score [ASDAS-CRP], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and patient-reported outcomes (pain), were assessed at 6, 12, 24, 36 and 48 months.
View Article and Find Full Text PDF